Oncology Xagena
Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...
Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and has shown encouraging activity in combination with ICIs ...
While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...
First-line immunotherapy with / without chemotherapy is standard of care for patients with advanced non-small-cell lung cancer ( NSCLC ); however, there is a need for effective treatment options after ...
Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...
Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...
Two-year ( 25.4 months minimum; 32.9 months median ) follow-up results from analyses of the phase 3 CheckMate -9ER trial, have demonstrated sustained survival and response rate benefits, as well as he ...
